No, sacubitril-valsartan (Entresto) should NOT be reduced to once-daily dosing
Sacubitril-valsartan must be administered twice daily as specified in the FDA-approved labeling and clinical practice guidelines—there is no evidence supporting once-daily dosing, and altering the approved regimen may compromise therapeutic efficacy. 1
Why Twice-Daily Dosing is Mandatory
The FDA label explicitly states that the recommended dosing for adult heart failure is twice daily, with a starting dose of 49/51 mg twice daily and a target maintenance dose of 97/103 mg twice daily 1. This dosing schedule is based on the pharmacokinetic profile of the drug:
- Sacubitril reaches peak plasma concentration in 0.5 hours
- LBQ657 (active metabolite) peaks at 2 hours
- Valsartan peaks at 1.5 hours
- Steady-state levels are achieved in 3 days with twice-daily dosing 1
The landmark clinical trials (PARADIGM-HF, PARAGON-HF, PARAGLIDE-HF) that demonstrated mortality and morbidity benefits all used twice-daily dosing 2, 3, 4. There are no randomized controlled trials evaluating once-daily administration.
Critical Context for Your Patient
Your patient has normal left ventricular size, good wall motion, and preserved systolic function—this clinical picture suggests heart failure with preserved ejection fraction (HFpEF), not HFrEF. This is a crucial distinction:
If This is HFpEF:
- Sacubitril-valsartan has demonstrated benefit in HFpEF, particularly in patients with LVEF ≤60% 3, 4
- The 2023 ACC Expert Consensus recommends sacubitril-valsartan as guideline-directed medical therapy for HFpEF 3
- Dosing remains twice daily: starting at 24/26 mg twice daily, titrating to 97/103 mg twice daily 3
If Considering Dose Reduction (Not Frequency):
The evidence strongly favors higher doses over lower doses:
- A dose-response study showed that the 24/26 mg dose had significantly higher HF hospitalization rates (29.14%) and mortality (29.63%) compared to 97/103 mg dose (16.10% and 9.27% respectively) 5
- The 2022 AHA/ACC/HFSA guidelines emphasize titration to target doses shown efficacious in RCTs (Class I, Level A recommendation) 2
- Lower doses do not produce the same cardiovascular mortality and hospitalization benefits 2
Common Pitfalls to Avoid
Do not confuse dose reduction with frequency reduction: If tolerability is an issue, you can reduce the dose (e.g., from 97/103 mg to 49/51 mg twice daily), but maintain twice-daily frequency 1
Do not assume preserved function means no benefit: Recent pooled analyses show sacubitril-valsartan reduces cardiovascular events in HFpEF, especially with LVEF ≤60% 4
Do not settle for suboptimal dosing without attempting titration: Guidelines recommend titration every 1-2 weeks as tolerated 2. Even patients started on very low doses (25 mg twice daily) due to hypotension concerns showed similar NT-proBNP reductions and LVEF improvements when maintained on therapy 6
Practical Management Strategy
If your patient is experiencing side effects or you're concerned about tolerability:
- Reduce the dose (e.g., 49/51 mg or even 24/26 mg twice daily) but maintain twice-daily frequency 1
- Reassess every 2-4 weeks and attempt uptitration 2
- Monitor blood pressure, renal function, and potassium
- Consider that even lower doses (49/51 mg twice daily) show significantly better outcomes than 24/26 mg twice daily 5
Bottom line: The twice-daily dosing schedule is integral to the drug's pharmacokinetics and proven clinical benefit. Switching to once-daily dosing is not supported by any evidence and should not be done.